Monday, November 8, 2021
- 8:30AM-10:30AM
-
Abstract Number: 1316
Vitamin D Deficiency and Disease Activity in Patients with Spondyloarthritis
Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)- 8:30AM-10:30AM
-
Abstract Number: 1184
Voluntary Online Gout Module: Housestaff Utilization and Efficacy
Professional Education Poster (1170–1195)- 8:30AM-10:30AM
-
Abstract Number: 1154
What Do Patients Know About Biosimilars and How Satisfied Are They with the Educational Process? – A Systematic Comparison Between Rheumatologists and Nurse Specialists, Including Effects of Multiswitching
Patient Outcomes, Preferences, & Attitudes Poster III: Patient Preferences (1153–1169)- 8:30AM-10:30AM
-
Abstract Number: 1312
What Is the Optimal Screening Strategy for Early Recognition of Spondyloarthritis in Patients with Acute Anterior Uveitis?
Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)- 8:30AM-10:30AM
-
Abstract Number: 1353
Whole Blood Transcriptional Changes Following Treatment with Filgotinib in Patients with Psoriatic Arthritis
Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)- 8:30AM-10:30AM
-
Abstract Number: 1202
Widespread but Not Regional Non-articular Pain Influences Patient and Rheumatologist Reported Change in Clinical Disease Activity Index Scores over Time – Implications for Using Patient Ratings in Telehealth – a Study from the Canadian Early Arthritis Cohort
RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)- 8:30AM-10:30AM
-
Abstract Number: 1302
Year-3 Observational Follow-up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE Who Completed a Phase 4, 52-Week, Randomized, Double-Blind Placebo-Controlled Safety Study
SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)- 8:30AM-10:30AM
-
Abstract Number: 1201
Younger Age and Smoking Status Are Associated with Delayed Diagnosis of Rheumatoid Arthritis in a U.S. Veteran Population
RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)- 9:00AM-9:15AM
-
Abstract Number: 1420
Evaluation of SARS-CoV-2 Vaccine Response in a Multi-Racial/Ethnic Cohort of Patients with Systemic Lupus Erythematosus
Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: COVID-19 Vaccine Experience & Translational Science (1420–1423)- 9:15AM-9:30AM
-
Abstract Number: 1421
Efficacy and Tolerance of Vaccination Against COVID-19 in Patients with Systemic Lupus Erythematosus: The International VACOLUP Study
Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: COVID-19 Vaccine Experience & Translational Science (1420–1423)- 9:30AM-9:45AM
-
Abstract Number: 1422
Urinary CD163 Predicts Proliferative Lupus Nephritis in SLE Patients with Proteinuria: A Practical Liquid Biopsy Approach
Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: COVID-19 Vaccine Experience & Translational Science (1420–1423)- 9:45AM-10:00AM
-
Abstract Number: 1423
Ability of Soluble Immune Mediators and SLE-associated Autoantibody Specificities to Forecast Transition to Classified SLE and Inform a Lupus Classification Risk Immune Index
Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: COVID-19 Vaccine Experience & Translational Science (1420–1423)- 10:30AM-10:45AM
-
Abstract Number: 1430
Autoantibodies Stabilize Neutrophil Extracellular Traps in COVID-19
Abstracts: Innate Immunity (1430–1433)- 10:30AM-10:45AM
-
Abstract Number: 1434
Multiomic Study of Skin, Peripheral Blood and Serum: Is Serum Proteome a Reflection of Disease Process at the End-Organ Level in Systemic Sclerosis?